Three companies have agreed to recall all lots of the antipsychotic quetiapine in Canada due to potential contamination with the antibiotic clindamycin, according to an announcement from Health Canada, that country's federal health agency. The recall applies to 25 mg, 100 mg, 200 mg, and 300 mg doses manufactured by Cobalt Pharmaceuticals Company, Laboratories Riva Inc., and Sanis Health Inc. All three companies are advising physicians and other health care professionals to contact their patients who have been supplied with any quetiapine from these manufacturers "to help ensure a safe transition over to alternative authorized and not affected quetiapine products on the Canadian market," the agency said. The announcement also advises patients to immediately contact their health care provider with questions about their use of the medication, not to discontinue treatment without advice from their clinician, and to report any adverse reactions potentially related to quetiapine products to Health Canada. No adverse reports have been received by Health Canada to date.
The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.